A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Advanced NRAS-Mutant Melanoma · Advanced NRAS-Mutant Solid Tumors · NRAS Mutation · NRAS G12D · NRAS G13R · NRAS G13D · NRAS G12V · NRAS Q61R · NRAS Q61K · NRAS Q61L · NRAS Q61H · Advanced NRAS-mutant Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9
3 insiders sold shares within a month
Since Oct 28, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 180 (planned)
- Started
- Mar 9, 2026
- Main results expected
- May 31, 2029
- Fully finished
- Jun 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Maximum Tolerated Dose (MTD) and/or RP2D of RLY-8161
Measured over: Cycle 1 (28-day cycle) of treatment for MTD and at the end of every cycle (28-day cycle) for RP2D until treatment discontinuation, approximately 12 months
Part 1: Number of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs), with changes in vital signs, electrocardiograms (ECGs), and laboratory tests
Measured over: Cycle 1 (28-day cycle) of treatment and at the end of every cycle (28-day cycle) until 30 days after treatment discontinuation, approximately 13 months
Part 2: Objective Response Rate (ORR) of RLY-8161 as assessed by RECIST v1.1
Measured over: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9, since 2026-10-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07584226 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC